Source Paper
Interleukin-1β Immunoreactivity and Microglia Are Enhanced in the Rat Hippocampus by Focal Kainate Application: Functional Evidence for Enhancement of Electrographic Seizures
, et al.
Source Paper
, et al.
Journal of Neuroscience • 1999
Using immunocytochemistry and ELISA, we investigated the production of interleukin (IL)-1β in the rat hippocampus after focal application of kainic acid inducing electroencephalographic (EEG) seizures and CA3 neuronal cell loss. Next, we studied whether EEG seizures per se induced IL-1β and microglia changes in the hippocampus using bicuculline as a nonexcitotoxic convulsant agent. Finally, to address the functional role of this cytokine, we measured the effect of human recombinant (hr)IL-1β on seizure activity as one marker of the response to kainate. Three and 24 hr after unilateral intrahippocampal application of 0.19 nmol of kainate, IL-1β immunoreactivity was enhanced in glia in the injected and the contralateral hippocampi. At 24 hr, IL-1β concentration increased by 16-fold ( p < 0.01) in the injected hippocampus. Reactive microglia was enhanced with a pattern similar to IL-1β immunoreactivity. Intrahippocampal application of 0.77 nmol of bicuculline methiodide, which induces EEG seizures but not cell loss, enhanced IL-1β immunoreactivity and microglia, although to a less extent and for a shorter time compared with kainate. One nanogram of (hr)IL-1β intrahippocampally injected 10 min before kainate enhanced by 226% the time spent in seizures ( p < 0.01). This effect was blocked by coinjection of 1 µg (hr)IL-1β receptor antagonist or 0.1 ng of 3-((+)-2-carboxypiperazin-4-yl)-propyl-1-phosphonate, selective antagonists of IL-1β and NMDA receptors, respectively. Thus, convulsant and/or excitotoxic stimuli increase the production of IL-1β in microglia-like cells in the hippocampus. In addition, exogenous application of IL-1β prolongs kainate-induced hippocampal EEG seizures by enhancing glutamatergic neurotransmission.
Objective: To investigate whether EEG seizures induced by bicuculline methiodide (a non-excitotoxic convulsant) enhance IL-1β immunoreactivity and microglia changes in the hippocampus without causing neuronal cell loss
This is a Bicuculline-Induced Seizure Model protocol using rat as the model organism. The procedure involves 8 procedural steps, 1 equipment items, 4 materials. Extracted from a 1999 paper published in Journal of Neuroscience.
Model and subjects
rat • Not specified • unknown • Not specified • Not specified
Study window
~1 day study window | ~24.3 hours hands-on
Core workflow
Intrahippocampal bicuculline methiodide injection • EEG seizure monitoring • Tissue collection for immunocytochemistry
Primary readouts
Key equipment and reagents
Verified items
0
Direct vendor links
0
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
Use the page like this
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Perform unilateral intrahippocampal application of bicuculline methiodide to induce EEG seizures
Note: Bicuculline methiodide is a non-excitotoxic convulsant that induces seizures without causing neuronal cell loss
“Intrahippocampal application of 0.77 nmol of bicuculline methiodide, which induces EEG seizures but not cell loss”
Record and monitor electroencephalographic seizure activity following bicuculline injection
Note: Seizure activity serves as a marker of response to the convulsant
“measured the effect of human recombinant (hr)IL-1β on seizure activity as one marker of the response”
Collect hippocampal tissue at specified timepoints for analysis of IL-1β immunoreactivity and microglia changes
Note: Tissue collected from both injected and contralateral hippocampi
“Three and 24 hr after unilateral intrahippocampal application of 0.19 nmol of kainate, IL-1β immunoreactivity was enhanced”
Perform immunocytochemistry to assess IL-1β immunoreactivity and reactive microglia in hippocampal tissue
Note: Examine both injected and contralateral hippocampi for comparison
“Using immunocytochemistry and ELISA, we investigated the production of interleukin (IL)-1β in the rat hippocampus”
Perform ELISA to quantify IL-1β concentration in hippocampal tissue
Note: Measure IL-1β levels at 24 hours post-injection
“Using immunocytochemistry and ELISA, we investigated the production of interleukin (IL)-1β”
Intrahippocampally inject human recombinant IL-1β 10 minutes before kainate application
Note: Used to test functional role of IL-1β in seizure activity
“One nanogram of (hr)IL-1β intrahippocampally injected 10 min before kainate enhanced by 226% the time spent in seizures”
Measure and quantify the time spent in seizures following IL-1β pre-treatment and kainate injection
Note: Primary outcome measure for IL-1β functional effects
“enhanced by 226% the time spent in seizures ( p < 0.01)”
Co-inject IL-1β receptor antagonist or NMDA receptor antagonist with IL-1β to block seizure enhancement
Note: Tests whether IL-1β effects are mediated through IL-1β and NMDA receptors
“This effect was blocked by coinjection of 1 µg (hr)IL-1β receptor antagonist or 0.1 ng of 3-((+)-2-carboxypiperazin-4-yl)-propyl-1-phosphonate”
This section explains what the experiment is doing, which readouts matter, what the data artifacts usually look like, and how the analysis should flow from raw capture to reported result.
To investigate whether EEG seizures induced by bicuculline methiodide (a non-excitotoxic convulsant) enhance IL-1β immunoreactivity and microglia changes in the hippocampus without causing neuronal cell loss
Objective
To investigate whether EEG seizures induced by bicuculline methiodide (a non-excitotoxic convulsant) enhance IL-1β immunoreactivity and microglia changes in the hippocampus without causing neuronal cell loss
Subjects
From paperrat • Not specified • unknown • Not specified • Not specified
Cohort notes
From paperUnilateral intrahippocampal injection procedure performed
Intrahippocampal bicuculline methiodide injection (Not specified)
EEG seizure monitoring (Not specified)
Tissue collection for immunocytochemistry (3 and 24 hours after injection)
Immunocytochemistry analysis (Not specified)
IL-1β immunoreactivity in hippocampal glia
From paperStatistical significance determined using p-values (p < 0.01 reported for IL-1β concentration increase and seizure duration enhancement)
Artifact type
Endpoint measurements summarized by group or timepoint
Comparison focus
Compare endpoint magnitude between groups, timepoints, or both
IL-1β concentration (fold increase measured by ELISA)
From paperStatistical significance determined using p-values (p < 0.01 reported for IL-1β concentration increase and seizure duration enhancement)
Artifact type
Endpoint measurements summarized by group or timepoint
Comparison focus
Compare endpoint magnitude between groups, timepoints, or both
Reactive microglia presence and distribution
From paperStatistical significance determined using p-values (p < 0.01 reported for IL-1β concentration increase and seizure duration enhancement)
Artifact type
Endpoint measurements summarized by group or timepoint
Comparison focus
Compare endpoint magnitude between groups, timepoints, or both
EEG seizure activity and duration
From paperStatistical significance determined using p-values (p < 0.01 reported for IL-1β concentration increase and seizure duration enhancement)
Artifact type
Endpoint measurements summarized by group or timepoint
Comparison focus
Compare endpoint magnitude between groups, timepoints, or both
IL-1β immunoreactivity in hippocampal glia
From paperRaw artifact
Per-sample or per-animal endpoint measurements collected during the experiment
Processed artifact
Structured table with cleaned measurements ready for comparison
Final reported form
Summary statistics and between-group or across-timepoint comparisons
IL-1β concentration (fold increase measured by ELISA)
From paperRaw artifact
Per-sample or per-animal endpoint measurements collected during the experiment
Processed artifact
Structured table with cleaned measurements ready for comparison
Final reported form
Summary statistics and between-group or across-timepoint comparisons
Reactive microglia presence and distribution
From paperRaw artifact
Per-sample or per-animal endpoint measurements collected during the experiment
Processed artifact
Structured table with cleaned measurements ready for comparison
Final reported form
Summary statistics and between-group or across-timepoint comparisons
EEG seizure activity and duration
From paperRaw artifact
Per-sample or per-animal endpoint measurements collected during the experiment
Processed artifact
Structured table with cleaned measurements ready for comparison
Final reported form
Summary statistics and between-group or across-timepoint comparisons
Acquisition
Collect raw experimental outputs with enough metadata to preserve sample identity, condition, and timing.
Preprocessing / cleaning
Statistical significance determined using p-values (p < 0.01 reported for IL-1β concentration increase and seizure duration enhancement)
Scoring or quantification
Quantify the primary readouts for this experiment: IL-1β immunoreactivity in hippocampal glia; IL-1β concentration (fold increase measured by ELISA); Reactive microglia presence and distribution; EEG seizure activity and duration.
Statistical comparison
Statistical method not yet structured for this page.
Reporting output
Report representative outputs alongside summary comparisons for IL-1β immunoreactivity in hippocampal glia, IL-1β concentration (fold increase measured by ELISA), Reactive microglia presence and distribution, EEG seizure activity and duration.
Source links and direct wording from the methods section for validation and deeper review.
Citation
Annamaria Vezzani et al. (1999). Interleukin-1β Immunoreactivity and Microglia Are Enhanced in the Rat Hippocampus by Focal Kainate Application: Functional Evidence for Enhancement of Electrographic Seizures. Journal of Neuroscience
“”
“”
“”
“”
Direct vendor pages are linked from the protocol above. This section stays focused on the full comparison view and the prep checklist.
Gather these items before starting the experiment. Check off items as you prepare.
Not specified • Not specified • Not specified • Not specified
Not specified • Not specified • Not specified • Not specified
Not specified • Not specified • Not specified • Not specified
Not specified • Not specified • Not specified • Not specified
Not specified • Not specified • Not specified • Not specified
Not specified • Not specified
Use this section as the page quality checkpoint. It keeps section navigation, evidence access, readiness, and verification meaning in one place.
Current status surfaces were computed from experiment data updated Feb 28, 2026.
Source access
Jump back into the original paper or the methods evidence section when you need exact wording, exclusions, or method-specific caveats.
This protocol has structured steps plus evidence quotes, and is ready for canonical sync.
Steps
8
Evidence Quotes
13
Protocol Items
5
Linked Products
0
Canonical Sync
Pending
What this means
The completeness score reflects how much structured protocol data is present: steps, methods evidence, listed materials, linked products, and paper provenance.
Computed from the current experiment record updated Feb 28, 2026.
Canonical Sync shows whether a ConductGraph-backed protocol is available for this experiment route right now. It is a sync-status signal, not a claim that every downstream vendor link or step detail is perfect.
Steps
8
Evidence
13
Specific Products
0/0
Canonical Sync
Pending
What this score means
The verification score reflects evidence coverage, subject detail, paper provenance, step depth, and whether linked products resolve to specific item pages instead of generic searches.
Computed from the current experiment record updated Feb 28, 2026.
A page can have structured steps and still need review when evidence is thin, product links are generic, or canonical protocol coverage is still pending.
What still needs work